Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
24
Recruiting, any sponsor type, condition "hypertrophic cardiomyopathy"
By trial status
The same filters, counted in each status. Pick one to switch.
24 trials
Showing 1 to 24, recently updated first.
Atrium TherapeuticsIndustry
NCT07738107 · 37 participants (planned) · Start Sep 14, 2026 · Primary completion May 2028
Drug: ATR 1072 · For: Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic and 1 more
Sites: Kansas City, Missouri; Houston, Texas
- BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic CardiomyopathyPivotal-lookingRecruiting
Braveheart Bio, Inc.Industry
NCT07755904 · 210 participants (planned) · Start Sep 2, 2026 · Primary completion Oct 2028
Drug: BHB-1893; Metoprolol · For: Cardiomyopathy, Hypertrophic Obstructive
Sites: Burlington, Massachusetts; Manhasset, New York; Rock Hill, South Carolina · 4 sites in all
- Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001Recruiting
Haya Therapeutics, Inc.Industry
NCT07867288 · 10 participants (planned) · Start Oct 30, 2026 · Primary completion Mar 2027
Drug: HTX-001 · For: Nonobstructive Hypertrophic Cardiomyopathy
Sites: Boston, Massachusetts; Kansas City, Missouri; Cincinnati, Ohio
- Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH TrialRecruiting
University of ManchesterAcademic, hospital or other
NCT07120776 · 75 participants (planned) · Start Mar 26, 2026 · Primary completion Oct 2028
Drug: Camzyos (Mavacamten) · For: Hypertrophic Obstructive Cardiomyopathy \(HOCM\); Left Ventricular Outflow Tract Obstruction; Myocardial Ischaemia
Sites: Manchester, United Kingdom
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07361289 · 500 participants (planned) · Start Jan 15, 2026 · Primary completion Aug 22, 2028
Drug: Mavacamten · For: Hypertrophic Cardiomyopathy
Sites: Beijing, China; Guangzhou, China; Jiazhuang, China · 15 sites in all
- A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic CardiomyopathyPivotal-lookingRecruiting
Imbria Pharmaceuticals, Inc.Industry
NCT07023614 · 165 participants (planned) · Start Oct 6, 2025 · Primary completion Dec 2026
Drug: Ninerafaxstat 200mg MR; Placebo · For: Non-obstructive Hypertrophic Cardiomyopathy
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 76 sites in all
- Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's AtaxiaRecruiting
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT05302271 · 25 participants (planned) · Start Feb 22, 2022 · Primary completion Dec 31, 2028
Drug: AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN; Prednisone · For: Friedreich Ataxia; Cardiomyopathies; Cardiac Hypertrophy and 1 more
Sites: New York, New York
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05489705 · 1,700 participants (planned) · Start Aug 16, 2022 · Primary completion Aug 17, 2029
Drug: Mavacamten; Non-mavacamten symptomatic oHCM therapy · For: Obstructive Hypertrophic Cardiomyopathy
Sites: Anchorage, Alaska; Tucson, Arizona; Little Rock, Arkansas · 101 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07541833 · 36 participants (planned) · Start Feb 5, 2026 · Primary completion Dec 31, 2026
Drug: Mavacamten · For: Cardiomyopathy
Sites: Minato-ku, Japan
- LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.Pivotal-lookingRecruiting
Rennes University HospitalAcademic, hospital or other
NCT07202897 · 532 participants (planned) · Start Jan 7, 2026 · Primary completion Jan 7, 2032
Drug: Anticoagulant treatment Rivaroxaban · For: Hypertrophic Cardiomyopathy (HCM)
Sites: Angers, France; Bordeaux, France; Brest, France · 17 sites in all
- Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic CardiomyopathyRecruiting
Oregon Health and Science UniversityAcademic, hospital or other
NCT07600177 · 40 participants (planned) · Start May 5, 2026 · Primary completion Dec 31, 2026
Drug: Aficamten · For: Hypertrophic Cardiomyopathy (HCM)
Sites: Kansas City, Missouri; Portland, Oregon
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07557498 · 362 participants (planned) · Start Jan 15, 2026 · Primary completion Dec 14, 2026
Drug: Mavacamten · For: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Sites: Bollington, United Kingdom
China National Center for Cardiovascular DiseasesGovernment (non-federal)
NCT07367724 · 44 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2027
Drug: Ademetionine 1,4-Butanedisulfonate; Placebo · For: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Sites: Beijing, China; Shanghai, China; Xinjiang, China
- Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related DiseasesRecruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT07464132 · 30 participants (planned) · Start Dec 17, 2025 · Primary completion Feb 17, 2027
Drug: Injection of 68Ga-NI-FAPI · For: Tumor; Cardiovascular Diseases; Pulmonary Fibrosis and 3 more
Sites: Beijing, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07383025 · 200 participants (planned) · Start May 21, 2025 · Primary completion Nov 30, 2029
Drug: Mavacamten · For: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Sites: Tokyo, Japan
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05939700 · 20 participants (planned) · Start Nov 9, 2023 · Primary completion Apr 30, 2027
Drug: Mavacamten · For: Breastfeeding; Hypertrophic Cardiomyopathy; Pregnancy Related
Sites: Wilmington, North Carolina
- A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic CardiomyopathyRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07021963 · 300 participants (planned) · Start Jul 4, 2025 · Primary completion Dec 2027
Drug: HRS-1893 Tablet · For: Hypertrophic Cardiomyopathy
Sites: Beijing, China
Medical University of ViennaAcademic, hospital or other
NCT07150299 · 20 participants (planned) · Start Sep 5, 2025 · Primary completion May 2027
Drug: Mavacamten in clinical routine use · For: Hypertrophic Obstructive Cardiomyopathy \(HOCM\)
Sites: Vienna, Austria
- Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic CardiomyopathyPivotal-lookingRecruiting
Morten Steen Kvistholm JensenAcademic, hospital or other
NCT05569382 · 100 participants (planned) · Start Aug 10, 2022 · Primary completion Apr 1, 2027
Drug: Verapamil; Bisoprolol and 1 more · For: Non-obstructive Hypertrophic Cardiomyopathy
Sites: Aarhus N, Denmark; Odense, Denmark; Roskilde, Denmark · 4 sites in all
- ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathyPivotal-lookingRecruiting
Yonsei UniversityAcademic, hospital or other
NCT06580717 · 200 participants (planned) · Start Oct 15, 2024 · Primary completion Nov 30, 2026
Drug: enavogliflozin 0.3mg; enavogliflozin Placebo · For: Nonobstructive Hypertrophic Cardiomyopathy
Sites: Seoul, South Korea
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06551129 · 118 participants (planned) · Start May 10, 2024 · Primary completion Dec 31, 2026
Drug: Mavacamten · For: Obstructive Hypertrophic Cardiomyopathy
Sites: Boston, Massachusetts
Michael AyersAcademic, hospital or other
NCT06023186 · 20 participants (planned) · Start Nov 3, 2023 · Primary completion Aug 31, 2026
Drug: mavacamten · For: Obstructive Hypertrophic Cardiomyopathy
Sites: Charlottesville, Virginia
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06146660 · 600 participants (planned) · Start Jul 24, 2024 · Primary completion Nov 30, 2026
Drug: Mavacamten · For: Obstructive Hypertrophic Cardiomyopathy
Sites: Seoul, South Korea · 2 sites in all
- MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathiesRecruiting
Medical University of WarsawAcademic, hospital or other
NCT06555237 · 40 participants (planned) · Start Aug 1, 2024 · Primary completion Aug 1, 2026
Drug: Trametinib tablet; Standard therapy · For: Cardiomegaly; Noonan Syndrome
Sites: Warsaw, Poland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.